Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- DECK +14.3%, MGRC +14%, CNC +12.8%, BAH +11.7%, NWL +11.3%, WDC +10.3%, DLR +9.9%, SKX +7.7%, APPF +5.4% (also CFO steps down; also co acquires LiveEasy, a concierge platform), MTX +5%, COF +4.7%, BCPC +4.7%, RMD +4.6%, LHX +4.4%, WT +4%, SXT +3.9%, ZYXI +3.6%, NWG +3.2%, AON +2.9%, STEL +2.9%, VTMX +2.8%, SNY +2.8%, NOV +2.1%, POR +1.4%, CRI +1.3%, LKFN +1.3%, KNSL +1.2% (also authorizes new $100 mln share repurchase program), BYD +1.2%
Other news:
- TPR +15.9% (judge has blocked TPR acquisition of CPRI, according to CNBC; Issues Statement on District Court Ruling)
- IDYA +7.9% (announces positive interim Phase 1 expansion data of IDE397 in MTAP-deletion urothelial and lung cancer as late-breaker oral presentation at EORTC-NCI-AACR 2024)
- ANIP +7.8% (announces the FDA approval and launch of estradiol gel, 0.06%)
- LYEL +7.3% (to acquire ImmPACT Bio USA; also discontinuing development of LYL797, LYL845 and earlier-stage TIL programs)
- SAVE +7% (discloses it entered into a binding term sheet with GA Telesis or the sale of 23 A320ceo/A321ceo aircraft; provides Q3 guidance metrics)
- TYRA +4.9% (Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer)
- SUM +3.5% (receives non-binding acquisition proposal)
- PPBT +2.9% (new data regarding its tri-specific antibody platform, CAPTN-3)
- EPSN +2.7% (to form a joint venture in Canada)
- DFS +2.1% (in sympathy with COF)
- GVA +1.3% (awarded $21 mln contract by the Cal DoT)
- TSM +1.1% (Arizona plant production yields 4 percentage points higher than its Taiwan factories, according to Bloomberg)
- SEDG +1% (applauds Treasury Dept's Final Rule)
- AUB +1% (increases dividend)
- VALE +1% (reports Q3 trading update)
- TPX +1% (announces close of $1.6 billion term loan B facility)